
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Essex Bio-Technology Limited (“Company”), you should at once hand this circular together with the accompanying form of proxy to the purchaser or the transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the annual general meeting of the Company to be held at Regus Conference Centre, 35th Floor, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong on Wednesday, 12 May 2021 at 2:00 p.m. (the “AGM”) is set out on pages 22 to 27 of this circular.

A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the meeting, you are requested to complete and return the accompanying form of proxy in accordance with the instructions printed thereon and deposit the same as soon as possible and in any event not later than 48 hours before the time of the meeting or any adjournment thereof to the branch share registrar of the Company in Hong Kong, Hong Kong Registrars Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Hong Kong. Completion and return of the form of proxy will not preclude you from attending and voting in person at the meeting or any adjournment thereof should you so wish, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

PRECAUTIONARY MEASURES FOR THE AGM

Please see page 1 of this circular for measures being taken to try to prevent and control the spread of the COVID-19 at the AGM, including:

- compulsory temperature checks
- compulsory wearing of surgical face masks
- no distribution of corporate gifts and refreshments

Any person who does not comply with the precautionary measures may be denied entry into the AGM venue. For the health and safety of the Shareholders, the Shareholders are encouraged to exercise their right to vote at the AGM by appointing the Chairman of the AGM as their proxy to vote on the relevant resolutions as an alternative to attending the AGM in person.

CONTENTS

	<i>Page</i>
PRECAUTIONARY MEASURES FOR THE AGM.	1
DEFINITIONS	3
LETTER FROM THE BOARD	5
APPENDIX I – EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE	10
APPENDIX II – DETAILS OF THE DIRECTORS PROPOSED TO BE RE-ELECTED AT THE ANNUAL GENERAL MEETING	17
NOTICE OF ANNUAL GENERAL MEETING	22

PRECAUTIONARY MEASURES FOR THE AGM

In view of the ongoing novel coronavirus (“**COVID-19**”) epidemic and the requirements for prevention and control of its spread, the Company will implement the following preventive measures at the AGM to protect attending shareholders, staff and other stakeholders from the risk of infection:

- (i) compulsory body temperature checks will be conducted on every shareholder, proxy and other attendees at the entrance of the AGM venue. Any person with a body temperature of over 37.4 degrees Celsius will be denied entry into the AGM venue or be required to leave the AGM venue;
- (ii) all attendees are required to wear surgical face masks before they are permitted to attend, and throughout their attendance of the AGM at all times, and they are encouraged to maintain a safe distance between seats; and
- (iii) no refreshments will be served, and there will be no corporate gifts.

To the extent permitted under law, the Company reserves the right to deny entry into the AGM venue or require any person to leave the AGM venue in order to ensure the safety of the attendees at the AGM.

In the interest of all stakeholders’ health and safety and consistent with the latest COVID-19 guidelines for prevention and control, the Company reminds all shareholders that physical attendance in person at the AGM is not necessary for the purpose of exercising voting rights. As an alternative, by using proxy forms with voting instructions inserted, shareholders may appoint the Chairman of the AGM as their proxy to vote on the relevant resolutions at the AGM instead of attending the AGM in person.

The proxy form is attached to this circular for shareholders who opt to receive physical circulars. Alternatively, the proxy form can be downloaded from the “Investor Relations” section of the Company’s website at www.essexbio.com. If you are not a registered shareholder (if your shares are held via banks, brokers, custodians or the Hong Kong Securities Clearing Company Limited), you should consult directly with your banks or brokers or custodians (as the case may be) to assist you in the appointment of proxy.

PRECAUTIONARY MEASURES FOR THE AGM

If shareholders choosing not to attend the AGM in person have any questions about the relevant resolutions, or about the Company, or any matters for communication with the Board, they are welcome to contact the Company through the company secretary of the Company whose contact details are as follows:

Email: essex@essexbio.com

Tel: (852) 2587 7838

Fax: (852) 2587 7363

If shareholders have any questions relating to the AGM, please contact Computershare Hong Kong Investor Services Limited, the Company's share registrar as follows:

Hong Kong Registrars Limited

17M Floor, Hopewell Centre

183 Queen's Road East

Wanchai, Hong Kong

Website: www.computershare.com/hk/contact

Tel: (852) 2862 8555

Fax: (852) 2865 0990

Subject to the development of the COVID-19, the Company may implement further changes and precautionary measures in relation to the AGM arrangements at short notice to comply with the requirements of the Hong Kong Government. Shareholders are reminded to check the Company's website at regular intervals for further announcements and updates on the AGM arrangements. For the avoidance of doubt, the Company reserves the right to change the conditions in relation to the AGM in the event of changes in government regulations and non-adherence to any government regulations and/or precautionary measures in relation to the AGM arrangements by attendees at the AGM.

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“AGM”	the annual general meeting of the Company to be held at Regus Conference Centre, 35th Floor, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong on Wednesday, 12 May 2021 at 2:00 p.m. (or any adjournment thereof)
“AGM Notice”	the notice convening the AGM set out on pages 22 to 27 of this circular
“Articles”	the existing articles of association of the Company
“Board”	the board of Directors
“Companies Law”	the Companies Law, Cap 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands
“Company”	Essex Bio-Technology Limited (億勝生物科技有限公司), a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Stock Exchange
“Director(s)”	director(s) of the Company
“Extension Mandate”	as defined in paragraph 4 of the “Letter from the Board” contained in this circular
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Issue Mandate”	as defined in paragraph 4 of the “Letter from the Board” contained in this circular

DEFINITIONS

“Latest Practicable Date”	22 March 2021, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Memorandum”	the existing memorandum of association of the Company
“Repurchase Mandate”	as defined in paragraph 4 of the “Letter from the Board” contained in this circular
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong
“Share(s)”	ordinary share(s) of nominal value of HK\$0.10 each in the share capital of the Company
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers

LETTER FROM THE BOARD



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

Executive Directors:

Mr. Ngiam Mia Je Patrick (*Chairman*)
Mr. Fang Haizhou
Mr. Ngiam Hian Leng Malcolm
Ms. Yau Lai Man

Registered Office:

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

Independent non-executive Directors:

Mr. Fung Chi Ying
Mr. Mauffrey Benoit Jean Marie
Ms. Yeow Mee Mooi

*Head office and principal place of
business in Hong Kong:*

Room 2818
China Merchants Tower
Shun Tak Centre
168-200 Connaught Road Central
Hong Kong

26 March 2021

To the Shareholders

Dear Sir or Madam,

**PROPOSALS FOR
GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES
AND
RE-ELECTION OF DIRECTORS**

1. INTRODUCTION

The purpose of this circular is to provide you with information in respect of the resolutions to be proposed at the AGM relating to, among other matters, the proposed grant of the Issue Mandate, the Repurchase Mandate and the Extension Mandate, and the re-election of Directors.

LETTER FROM THE BOARD

2. ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS AND THE REPORTS OF THE DIRECTORS AND THE AUDITORS

The annual report 2020 incorporating the audited consolidated financial statements of the Company and the reports of the Directors and the auditors for the year ended 31 December 2020 will be sent together with this circular to the Shareholders on the same date. The audited consolidated financial statements of the Company have been reviewed by the audit committee of the Company.

3. DECLARATION OF FINAL DIVIDEND

The Board has recommended a final dividend of HK\$0.05 per Share for the year ended 31 December 2020 in cash and such final dividend will be payable on Tuesday, 1 June 2021.

The register of members of the Company will be closed from Tuesday, 18 May 2021 to Friday, 21 May 2021, both days inclusive, for ascertaining shareholders' entitlement to the proposed final dividend. During this period, no transfer of Shares will be registered. In order to qualify for the proposed final dividend to be approved at the AGM, all transfers of Shares accompanied by the relevant share certificates and properly completed transfer forms must be lodged with the branch share registrar of the Company in Hong Kong, Hong Kong Registrars Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration not later than 4:30 p.m. on Monday, 17 May 2021.

4. GENERAL MANDATES TO ISSUE AND TO REPURCHASE SHARES

At the AGM, an ordinary resolution will be proposed to approve the granting to the Directors of a general and unconditional mandate to allot, issue or deal with issued Shares up to a maximum of 20% of the aggregate number of Shares in issue as at the date of passing the relevant resolution ("**Issue Mandate**"). As at the Latest Practicable Date, a total of 576,651,000 Shares were in issue. Subject to the passing of the proposed resolution granting the Issue Mandate to the Directors and on the basis that no Shares will be issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Issue Mandate to issue a maximum of 115,330,200 Shares.

At the AGM, an ordinary resolution will also be proposed to approve the granting to the Directors of a general and unconditional mandate to exercise all powers of the Company to repurchase, on the Stock Exchange or on any other stock exchange on which the Shares may be listed, Shares up to a maximum of 10% of the number of Shares in issue as at the date of passing such resolution ("**Repurchase Mandate**"). As at the Latest Practicable Date, a total of 576,651,000 Shares were in issue. Subject to the passing of the proposed resolution granting the Repurchase Mandate to the Directors and on the basis that no Shares will be issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 57,665,100 Shares.

LETTER FROM THE BOARD

In addition, an ordinary resolution will be proposed at the AGM that any Shares repurchased under the Repurchase Mandate (up to a maximum of 10% of the aggregate number of Shares in issue as at the date of the grant of the Repurchase Mandate) will be added to the total number of Shares of which may be allotted and issued under the Issue Mandate (“**Extension Mandate**”).

Each of the Issue Mandate, the Repurchase Mandate and the Extension Mandate will expire at the earliest of: (a) the conclusion of the next annual general meeting of the Company; or (b) the end of the period within which the Company is required by the Companies Law or the Articles to hold its next annual general meeting; or (c) when revoked or varied by ordinary resolution(s) of the Shareholders in general meeting prior to the next annual general meeting of the Company. The Board wishes to state that with regard to the Issue Mandate, it has no immediate plan to issue any Shares pursuant thereto, and with regard to the Repurchase Mandate, the Board may or may not repurchase any Shares pursuant thereto depending on the prevailing market conditions.

Under the Listing Rules, the Company is required to give to all Shareholders all information which is reasonably necessary to enable Shareholders to make an informed decision as to whether to vote for or against the resolution in respect of the Repurchase Mandate at the AGM. An explanatory statement for such purpose is set out in Appendix I to this circular.

5. RE-ELECTION OF DIRECTORS

In compliance with the Articles, each of Mr. Ngiam Mia Je Patrick (an executive Director), Mr. Fang Haizhou (an executive Director) and Mr. Fung Chi Ying (an independent non-executive Director) will retire as Director by rotation and, being eligible, offer himself for re-election as Director at the AGM.

Pursuant to the Articles and the Corporate Governance Code as set out in Appendix 14 to the Listing Rules, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man, being the newly appointed executive Directors, will only hold their respective office until the AGM and, being eligible, offer themselves for re-election as Directors at the AGM.

Particulars of each of the aforesaid Directors are set out in Appendix II to this circular.

6. RE-APPOINTMENT OF AUDITORS

The Board (which agreed with the view of the audit committee of the Company) recommended that, subject to the approval of the Shareholders at the AGM, BDO Limited be re-appointed as the auditors of the Company for the year ending 31 December 2021.

LETTER FROM THE BOARD

7. AGM AND PROXY ARRANGEMENT

The AGM Notice is set out on pages 22 to 27 of this circular. At the AGM, resolutions will be proposed to approve, among other matters, the grant of the Issue Mandate, the Repurchase Mandate and the Extension Mandate, the re-election of Directors and the declaration of the final dividend for the year ended 31 December 2020.

The register of members of the Company will be closed from Friday, 7 May 2021 to Wednesday, 12 May 2021, both days inclusive, for ascertaining shareholders' right to attend and vote at the AGM. During this period, no transfer of Shares will be registered. In order to be entitled to attend the AGM, all transfers of Shares accompanied by the relevant share certificates and properly completed transfer forms must be lodged with the branch share registrar of the Company in Hong Kong, Hong Kong Registrars Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration not later than 4:30 p.m. on Thursday, 6 May 2021.

A form of proxy for use at the AGM is enclosed with this circular. Whether or not you are able to attend the AGM in person, you are requested to complete and return the accompanying form of proxy in accordance with the instructions printed thereon as soon as possible and in any event not later than 48 hours before the time for holding the AGM or any adjournment thereof to the branch share registrar of the Company in Hong Kong, Hong Kong Registrars Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish, and in such case, the form of proxy previously submitted shall be deemed to be revoked.

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of shareholders at a general meeting must be taken by poll. Therefore, all resolutions proposed at the AGM shall be voted by poll. An announcement on the poll vote results will be made by the Company after the AGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

To the best of the Director's knowledge, information and belief, having made all reasonable enquiries, (i) no Shareholder is required to abstain from voting on the resolutions to be proposed at the AGM; and (ii) as at the Latest Practicable Date, there was no voting trust or other agreement or arrangement or understanding (other than an outright sale) entered into by or binding upon any Shareholder and there was no obligation or entitlement of any Shareholder whereby he/she/it has or may have temporarily or permanently passed control over the exercise of the voting right in respect of his/her/its Shares to a third party, either generally or on a case-by-case basis.

LETTER FROM THE BOARD

8. RECOMMENDATION

The Directors believe that the proposed grant of the Issue Mandate, the Repurchase Mandate and the Extension Mandate, and the re-election of Directors are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favour of all the resolutions set out in the AGM Notice.

9. GENERAL INFORMATION

Your attention is drawn to the additional information set out in the Appendices to this circular.

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
For and on behalf of the Board of
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

This Appendix serves as an explanatory statement, as required by the Listing Rules, to provide requisite information as to the proposed Repurchase Mandate.

1. THE LISTING RULES RELATING TO THE REPURCHASE OF SHARES

The Listing Rules permit companies whose primary listing is on the Stock Exchange to repurchase their shares on the Stock Exchange subject to certain restrictions. Among such restrictions, the Listing Rules provide that the shares of such company must be fully paid up and all repurchases of shares by such company must be approved in advance by an ordinary resolution of shareholders, either by way of a general repurchase mandate or by specific approval of a particular transaction.

2. SHARE CAPITAL

As at the Latest Practicable Date, there were a total of 576,651,000 Shares in issue.

Subject to the passing of the proposed resolution granting the Repurchase Mandate and on the basis that no further Shares are issued or repurchased prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 57,665,100 Shares.

3. REASONS FOR THE REPURCHASE

The Directors believe that it is in the best interests of the Company and the Shareholders as a whole to seek a general authority from the Shareholders to enable the Company to repurchase the Shares on the Stock Exchange. Share repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made when the Directors believe that such repurchase will benefit the Company and the Shareholders.

The Board wishes to state that it may or may not repurchase any Shares pursuant to the Repurchase Mandate depending on the prevailing market conditions.

4. FUNDING OF REPURCHASES

Repurchases made pursuant to the Repurchase Mandate would be funded out of funds legally available for the purpose in accordance with the Memorandum and Articles, the Companies Law and other applicable laws of the Cayman Islands. A listed company may not repurchase its own securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange. Under the Companies Law, repurchases by the Company may only be made out of profits of the Company or out of the proceeds of a fresh issue of Shares made for the purpose, or, if so authorised by the Articles and subject to the provisions of the Companies Law, out of capital. Any premium payable on a redemption or purchase over the par value of the Shares to be purchased must be provided for out of profits of the Company or out of the Company's share premium account, or, if so authorised by the Articles and subject to the provisions of the Companies Law, out of capital.

Taking into account the current working capital position of the Company, the Directors consider that, if the Repurchase Mandate were to be exercised in full, it might have a material adverse effect on the working capital and/or the gearing position of the Company as compared with the position as at 31 December 2020, being the date of its latest published audited financial statements. However, the Directors do not intend to make any repurchases to such an extent as would, in the circumstances, have a material adverse effect on the working capital requirements or the gearing position of the Company which in the opinion of the Directors are from time to time appropriate for the Company.

5. SHARE PRICES

The highest and lowest prices at which the Shares have been traded on the Stock Exchange in each of the 12 calendar months immediately preceding the Latest Practicable Date are as follows:

	Highest	Lowest
	<i>HK\$</i>	<i>HK\$</i>
March 2020	5.58	3.92
April 2020	5.33	4.03
May 2020	5.29	4.52
June 2020	5.87	4.70
July 2020	5.78	4.62
August 2020	5.27	4.72
September 2020	5.09	2.90
October 2020	4.51	3.90
November 2020	4.63	3.97
December 2020	4.27	3.71
January 2021	4.25	3.65
February 2021	4.86	3.92
March 2021 (up to the Latest Practicable Date)	6.57	4.52

6. THE TAKEOVERS CODE AND MINIMUM PUBLIC HOLDING

If a Shareholder's proportionate interest in the voting rights of the Company increases on the Company exercising its powers to repurchase Shares pursuant to the Repurchase Mandate, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert (as defined in the Takeovers Code) could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

APPENDIX I**EXPLANATORY STATEMENT
ON THE REPURCHASE MANDATE**

As at the Latest Practicable Date, according to the register kept by the Company pursuant to section 336 of the SFO and so far as was known to, or could be ascertained after reasonable enquiry by the Directors, the following persons were interested in 5% or more of the then issued share capital of the Company:

Name	Number of Shares/ underlying shares held	Approximate percentage of shareholding as at the Latest Practicable Date	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Ngiam Mia Je Patrick	153,945,667 <i>(Note 1)</i>	26.70%	29.66%
Ngiam Mia Kiat Benjamin	152,020,667 <i>(Notes 1(b) & 2)</i>	26.36%	29.29%
Lauw Hui Kian	153,945,667 <i>(Notes 1 & 3)</i>	26.70%	29.66%

Notes:

- 147,279,000 Shares were registered directly in the name of Ngiam Mia Je Patrick.
 - 6,666,667 Shares were held by Dynatech Ventures Pte Ltd (“**Dynatech**”), which was wholly owned by Essex Investment (Singapore) Pte Ltd (“**Essex Singapore**”). Since Essex Singapore was owned by Ngiam Mia Je Patrick and Ngiam Mia Kiat Benjamin in equal shares, each of Ngiam Mia Je Patrick and Ngiam Mia Kiat Benjamin was deemed to be interested in these Shares as each of them was entitled to exercise or control the exercise of more than one-third of the voting power of Dynatech at general meetings.
- 145,354,000 Shares were registered directly in the name of Ngiam Mia Kiat Benjamin.
 - 6,666,667 Shares were held by Dynatech.
- Lauw Hui Kian is the spouse of Ngiam Mia Je Patrick (an executive Director). For the purpose of Part XV of the SFO, Lauw Hui Kian was deemed to be interested in the 153,945,667 Shares in which Ngiam Mia Je Patrick was interested.

In the event that the Directors shall exercise in full the Repurchase Mandate, the total interests of the above substantial shareholders would be increased to approximately the respective percentages shown in the last column above (assuming that the number of Shares in which each of such persons is interested and the then number of total Shares then in issue remain the same), and such increase will not give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code.

Assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of a repurchase made pursuant to the Repurchase Mandate, an exercise of the Repurchase Mandate whether in whole or in part will not result in less than the relevant prescribed minimum percentage of the Shares being held by the public as required by the Stock Exchange. The Directors have no intention to exercise the Repurchase Mandate to an extent as may result in a public shareholding of less than such prescribed minimum percentage.

Save as disclosed above, the Directors are not aware of any Shareholder or group of Shareholders acting in concert, who may become obliged to make a mandatory offer under Rule 26 of the Takeovers Code as a consequence of any purchases made pursuant to the Repurchase Mandate.

7. SHARE REPURCHASE MADE BY THE COMPANY

The Company repurchased a total of 1,286,000 Shares on the Stock Exchange during the six months immediately preceding the Latest Practicable Date, details of which are as follows:

Date of repurchase	Number of Shares repurchased	Price paid per Share	
		Highest HK\$	Lowest HK\$
16 October 2020	155,000	4.22	4.15
19 October 2020	44,000	4.25	4.23
22 October 2020	110,000	4.38	4.34
23 October 2020	80,000	4.45	4.30
27 October 2020	40,000	4.40	4.18
5 November 2020	80,000	4.28	4.28
9 November 2020	40,000	4.30	4.30
10 November 2020	120,000	4.20	4.20
11 November 2020	230,000	4.20	4.10
13 November 2020	135,000	4.20	4.13
22 December 2020	10,000	3.99	3.99

APPENDIX I**EXPLANATORY STATEMENT
ON THE REPURCHASE MANDATE**

Date of repurchase	Number of Shares repurchased	Price paid per Share	
		Highest HK\$	Lowest HK\$
23 December 2020	5,000	4.00	4.00
24 December 2020	2,000	4.00	4.00
28 December 2020	2,000	4.00	4.00
29 December 2020	2,000	3.97	3.97
30 December 2020	1,000	4.05	4.05
4 January 2021	2,000	4.13	4.13
5 January 2021	5,000	3.94	3.94
7 January 2021	5,000	3.77	3.77
8 January 2021	14,000	3.77	3.77
11 January 2021	12,000	3.76	3.76
12 January 2021	9,000	3.83	3.83
13 January 2021	20,000	3.82	3.79
14 January 2021	10,000	3.80	3.80
15 January 2021	35,000	3.75	3.73
18 January 2021	30,000	3.71	3.70
19 January 2021	5,000	3.78	3.78
20 January 2021	30,000	3.80	3.76
22 January 2021	9,000	3.82	3.81
26 January 2021	19,000	3.97	3.89
27 January 2021	5,000	3.89	3.89
28 January 2021	5,000	3.90	3.90
29 January 2021	15,000	3.88	3.83

Save as disclosed above, the Company had not made any purchase of Shares (whether on the Stock Exchange or otherwise) during the six months immediately preceding the Latest Practicable Date.

8. GENERAL

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company if the Repurchase Mandate is approved by the Shareholders.

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will only exercise the power of the Company to make repurchases pursuant to the Repurchase Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands.

No core connected person (as defined in the Listing Rules) of the Company has notified the Company that he/she/it has a present intention to sell any Shares to the Company nor has any such core connected person undertaken not to sell any Shares held by him/her/it to the Company in the event that the Repurchase Mandate is granted.

PARTICULARS OF DIRECTORS FOR RE-ELECTION

The biographical details of the Directors eligible for re-election at the AGM are set out below:

Mr. Ngiam Mia Je Patrick

Mr. Ngiam Mia Je Patrick (“**Mr. Patrick Ngiam**”), aged 66, is the founder of the Group which was established in February 1999, an executive Director and the Chairman of the Company. He is a member of the remuneration committee and the nomination committee of the Company, a director of Essex Bio-Investment Limited, Essex Bio-Pharmacy Limited, Essex Healthtech Investment Limited, UNO Medical Group Limited, Essex Medipharma (Zhuhai) Company Limited, Zhuhai Essex Technology Development Company Limited, Zhuhai Essex Bio-Pharmaceutical Company Limited and UNO Medical (Zhuhai) Company Limited, all being subsidiaries of the Company. He is responsible for corporate planning, business development strategy and overall direction of the Group.

Mr. Patrick Ngiam graduated in electronics engineering and has received many accolades and awards for his achievements. Notably, in 1990, he was awarded the first KPMG Singapore High Tech Entrepreneur Award. Other awards include the DHL & Singapore Press Holdings Business Award for Businessman of the Year in 1994 and the Chevalier DE L’ORDRE NATIONAL DU MERITE conferred by Le President De La Republique Francaise in 1996.

The service contract between Mr. Patrick Ngiam and the Company has no fixed term but can be terminated by no less than six months’ notice in writing served by either party on the other. Mr. Patrick Ngiam is entitled to an annual salary of RMB1,750,000, which is determined with reference to his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Mr. Patrick Ngiam is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to his performance; and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Mr. Patrick Ngiam and the overall performance of the Group.

As at the Latest Practicable Date, Mr. Patrick Ngiam was directly interested in 147,279,000 Shares, and was also deemed to be interested in 6,666,667 Shares held by Dynatech Ventures Pte Ltd, a wholly-owned subsidiary of Essex Investment (Singapore) Pte Ltd, which in turn was owned by Mr. Patrick Ngiam and Mr. Ngiam Mia Kiat Benjamin (who is a director of a wholly-owned subsidiary of the Company and a substantial shareholder of the Company (as defined under the Listing Rules)) in equal shares. Mr. Patrick Ngiam is a brother of Mr. Ngiam Mia Kiat Benjamin and the father of Mr. Ngiam Hian Leng Malcolm (being an executive Director). Mr. Patrick Ngiam is also a director of each of Dynatech Ventures Pte Ltd and Essex Investment (Singapore) Pte Ltd. Mr. Patrick Ngiam is the Chairman and Chief Executive Officer of IPC Corporation Ltd and non-executive director of Wilton Resources Corporation Limited, which are both listed on the Singapore Exchange Securities Trading Limited.

Mr. Fang Haizhou

Mr. Fang Haizhou (“**Mr. Fang**”), aged 55, is an executive Director and the managing Director. He has a bachelor’s degree in Bio-chemical Engineering from Southern China Institute (華南工學院) and a master’s degree in Engineering from Southern China University of Technology (華南理工大學). Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Professor Level) by the Department of Human Resources and Social Security of the Guangdong Province. He has been with Zhuhai Essex Bio-Pharmaceutical Company Limited, a wholly-owned subsidiary of the Company, since its establishment in June 1996. Mr. Fang is also a director of Essex Bio-Investment Limited and Essex Bio-Pharmacy Limited, all being subsidiaries of the Company.

The service contract between Mr. Fang and the Company has no fixed term but can be terminated by no less than six months’ notice in writing served by either party on the other. Mr. Fang is entitled to an annual salary of RMB1,050,000, which is determined with reference to his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Mr. Fang is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to his performance; and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Mr. Fang and the overall performance of the Group.

As at the Latest Practicable Date, Mr. Fang was personally interested in 5,244,300 Shares.

Mr. Fung Chi Ying

Mr. Fung Chi Ying (“**Mr. Fung**”), aged 66, was appointed as an independent non-executive Director on 13 June 2001. Mr. Fung is the chairman of the audit committee and a member of the remuneration committee, the nomination committee and the corporate governance committee of the Company. Mr. Fung is a practising solicitor in Hong Kong. He is presently a partner of Adrian Yeung & Cheng, Solicitors. Mr. Fung’s current appointment is two years commencing from 30 September 2020, determinable by either party serving not less than one month’s written notice on the other. Mr. Fung is entitled to a fixed remuneration of HK\$250,000 per year, which is based on the estimated time to be spent by Mr. Fung for his duties as an independent non-executive Director.

Mr. Fung has served as an independent non-executive Director for more than 19 years. He meets the independence factors set out in Rule 3.13 of the Listing Rules and is not involved in the daily management of the Company nor in any relationships or circumstances which would interfere with the exercise of his independent judgment. In addition, he continues to demonstrate his ability to provide an independent, balanced and objective view to the affairs of the Company and there is no evidence that his tenure has had any impact on his independence. The Board is of the opinion that Mr. Fung remains independent notwithstanding the length of his service. Having due regard to the diversity policy of the Company, the nomination committee of the Board considers that Mr. Fung is able to provide valuable and relevant insights and contribute to the diversity of the Board, including his contribution to the Group’s compliance and internal control framework with his legal knowledge. The Board believes that his valuable knowledge and experience in the Group’s business and his general business acumen will continue to generate significant contribution to the Company and the Shareholders as a whole.

Mr. Ngiam Hian Leng Malcolm

Mr. Ngiam Hian Leng Malcolm (“**Mr. Malcolm Ngiam**”), aged 36, is an executive Director and the deputy managing Director. He is also the president of Essex Bio-Investment Limited, a wholly-owned subsidiary of the Company and a director of Essex Bio-Investment Limited, Essex Bio-Pharmacy Limited, Zhuhai Essex Bio-Pharmaceutical Company Limited and Majeton Pte. Ltd., all being subsidiaries of the Company. Mr. Malcolm Ngiam is principally responsible for strategic corporate planning, business development and overall operational management of the Group.

Prior to joining the Group in 2015, Mr. Malcolm Ngiam was involved in translational and therapeutics research for more than 10 years. Mr. Malcolm Ngiam leads the business development team of the Group for executing various investment projects and has direct oversight of the research and development and marketing functions of the Group. Mr. Malcolm Ngiam graduated from Imperial College London and has a bachelor’s degree in Biochemistry.

The service contract between Mr. Malcolm Ngiam and the Company has no fixed term but can be terminated by no less than six months' notice in writing served by either party on the other. Mr. Malcolm Ngiam is entitled to an annual salary of RMB910,000, which is determined with reference to his background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Mr. Malcolm Ngiam is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to his performance; and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Mr. Malcolm Ngiam and the overall performance of the Group.

Mr. Malcolm Ngiam is the son of Mr. Patrick Ngiam, the Chairman of the Company, and a nephew of Mr. Ngiam Mia Kiat Benjamin, a substantial shareholder of the Company. As at the Latest Practicable Date, Mr. Malcolm Ngiam was personally interested in 2,039,000 Shares and also held 1,000,000 share options of the Company.

Ms. Yau Lai Man

Ms. Yau Lai Man ("**Ms. Yau**"), aged 57, is an executive Director. She is also the company secretary and authorised representative of the Company and a member of the corporate governance committee of the Company. Ms. Yau is a director of Essex Bio-Investment Limited, Essex Bio-Pharmacy Limited, Zhuhai Essex Bio-Pharmaceutical Company Limited, Zhuhai Essex Technology Development Company Limited and UNO Medical (Zhuhai) Company Limited, all being subsidiaries of the Company. Ms. Yau is principally responsible for financial planning and management of the Group.

Prior to joining the Group in 2001, Ms. Yau had worked with a "big four" accounting firm and a multinational corporation. Ms. Yau is currently an independent non-executive director of Chu Kong Shipping Enterprises (Group) Company Limited, a company listed on the Main Board of the Stock Exchange (stock code: 560). Ms. Yau obtained a master degree in business administration from The University of Warwick in the United Kingdom. Ms. Yau is a member of the Hong Kong Institute of Certified Public Accountants and is also a member of the Institute of Chartered Accountants in England & Wales.

The service contract between Ms. Yau and the Company has no fixed term but can be terminated by no less than six months' notice in writing served by either party on the other. Ms. Yau is entitled to an annual salary of RMB1,533,000, which is determined with reference to her background, qualification, experience, duties and responsibilities within the Group and the prevailing market conditions. Ms. Yau is also entitled to (i) a variable salary to be determined by the Board at its absolute discretion having regard to her performance; and (ii) a discretionary bonus to be determined by the Board at its absolute discretion having regard to the performance of Ms. Yau and the overall performance of the Group.

As at the Latest Practicable Date, Ms. Yau was personally interested in 46,000 Shares.

Save as disclosed above, as at the Latest Practicable Date and to the best knowledge and belief of the Directors, the Directors confirmed that:

- (a) each of the above Directors did not have any other relationship with any Directors, senior management, substantial shareholders or controlling shareholders (which have the meaning ascribed to them respectively under the Listing Rules) of the Company;
- (b) each of the above Directors had no other interests in the shares of the Company within the meaning of Part XV of the SFO;
- (c) each of the above Directors did not hold any other positions in the Company or any member of the Group; and
- (d) each of the above Directors did not hold any other directorships in listed public companies in the last three years in Hong Kong or overseas.

GENERAL

Save as disclosed herein, the Board is not aware of any other matters which need to be brought to the attention of the Shareholders in relation to the above Directors and there is no other information which is discloseable pursuant to any of the requirements set out in Rule 13.51(2) of the Listing Rules.

NOTICE OF ANNUAL GENERAL MEETING



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting of Essex Bio-Technology Limited (“**Company**”) will be held at Regus Conference Centre, 35th Floor, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong on Wednesday, 12 May 2021 at 2:00 p.m. for the purpose of transacting the following business:

ORDINARY RESOLUTIONS

1. to receive and consider the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditors of the Company for the year ended 31 December 2020;
2. each as a separate resolution, to re-elect the retiring directors of the Company (namely, Mr. Ngiam Mia Je Patrick as an executive director of the Company, Mr. Fang Haizhou as an executive director of the Company, Mr. Fung Chi Ying as an independent non-executive director of the Company, Mr. Ngiam Hian Leng Malcolm as an executive director of the Company and Ms. Yau Lai Man as an executive director of the Company) and to authorise the board of directors to fix the remuneration of the directors of the Company;
3. to re-appoint BDO Limited as the auditors of the Company and to authorise the board of directors to fix their remuneration;
4. to consider and declare a final dividend of HK\$0.05 per share of the Company for the year ended 31 December 2020;

NOTICE OF ANNUAL GENERAL MEETING

and, to consider and, if thought fit, pass the following resolutions as Ordinary Resolutions (with or without modifications):

5. **“THAT:**
- (a) subject to paragraph (c) below, pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”), the exercise by the directors of the Company during the Relevant Period (as defined in paragraph (d) of this resolution) of all the powers of the Company to allot, issue or otherwise deal with unissued shares in the capital of the Company and to make or grant offers, agreements, options and other rights, including warrants to subscribe for shares of the Company and other securities, which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;
 - (b) the approval in paragraph (a) above shall authorise the directors of the Company during the Relevant Period (as defined in paragraph (d) of this resolution) to make or grant offers, agreements, options and other rights which might require the exercise of such powers after the end of the Relevant Period (as defined in paragraph (d) of this resolution);
 - (c) the aggregate number of shares of the Company allotted and issued or agreed conditionally or unconditionally to be allotted and issued (whether pursuant to options or otherwise) by the directors of the Company pursuant to the approval in paragraphs (a) and (b) above, otherwise than pursuant to (i) a Rights Issue (as defined in paragraph (d) of this resolution); or (ii) the exercise of any options granted under all share option schemes of the Company (or similar arrangements) adopted from time to time in accordance with the Listing Rules; or (iii) any scrip dividend or similar arrangements providing for the allotment and issue of shares of the Company in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company in force from time to time; or (iv) any issue of shares of the Company upon the exercise of rights of subscription or conversion under the terms of any warrants of the Company or any securities which are convertible into shares of the Company, shall not exceed the aggregate of:
 - (aa) 20 per cent. of the aggregate number of shares of the Company in issue as at the date of the passing of this resolution; and

NOTICE OF ANNUAL GENERAL MEETING

(bb) (if the directors of the Company are so authorised by a separate ordinary resolution of the shareholders of the Company) the aggregate number of shares of the Company purchased by the Company under the authority granted to the directors of the Company as referred to in resolution numbered 6 below,

and the authority pursuant to paragraphs (a) and (b) of this resolution shall be limited accordingly; and

(d) for the purposes of this resolution:

“**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or the law of the Cayman Islands or any other applicable laws to be held; and

(iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the directors of the Company by this resolution;

“**Rights Issue**” means an offer of shares of the Company, or offer or issue of warrants, options or other securities giving rights to subscribe for shares of the Company open for a period fixed by the directors of the Company to holders of shares of the Company on the Company’s register of members on a fixed record date in proportion to their then holdings of shares of the Company (subject to such exclusion or other arrangements as the directors of the Company may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expense or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction outside Hong Kong or any recognised regulatory body or any stock exchange outside Hong Kong).”

NOTICE OF ANNUAL GENERAL MEETING

6. **“THAT:**
- (a) subject to paragraph (b) below, the exercise by the directors of the Company during the Relevant Period (as defined in paragraph (c) of this resolution) of all powers of the Company to purchase shares in the capital of the Company on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”), or any other stock exchange on which the shares of the Company may be listed and which is recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the Securities and Futures Commission of Hong Kong, the Stock Exchange, the Companies Law, Chapter 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands and all other applicable laws in this regard, be and the same is hereby generally and unconditionally approved;
 - (b) the aggregate number of shares of the Company which may be purchased or agreed to be purchased by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period (as defined in paragraph (c) of this resolution) shall not exceed 10 per cent. of the aggregate number of shares of the Company in issue as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and
 - (c) for the purposes of this resolution, “**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or the law of the Cayman Islands or any other applicable laws to be held; and
 - (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the directors of the Company by this resolution.”

NOTICE OF ANNUAL GENERAL MEETING

7. “**THAT** conditional on the passing of resolutions numbered 5 and 6 above, the general mandate granted to the directors of the Company pursuant to resolution numbered 5 above be and is hereby extended by the addition to the aggregate number of shares of the Company which may be allotted, issued or dealt with or agreed conditionally or unconditionally to be allotted, issued or dealt with by the directors of the Company pursuant to or in accordance with such general mandate of an amount representing the aggregate number of shares of the Company purchased by the Company pursuant to or in accordance with the authority granted under resolution numbered 6 above, provided that such extended amount shall not exceed 10 per cent. of the aggregate number of shares of the Company in issue as at the date of passing of this resolution.”

For and on behalf of the Board of
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 26 March 2021

As at the date of this notice, the directors of the Company are as follows:

Executive directors:

Mr. Ngiam Mia Je Patrick (*Chairman*)
Mr. Fang Haizhou
Mr. Ngiam Hian Leng Malcolm
Ms. Yau Lai Man

Independent non-executive directors:

Mr. Fung Chi Ying
Mr. Mauffrey Benoit Jean Marie
Ms. Yeow Mee Mooi

*Head office and principal place of
business in Hong Kong:*

Room 2818
China Merchants Tower
Shun Tak Centre
168-200 Connaught Road Central
Hong Kong

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. A member entitled to attend and vote at the meeting convened by the above notice is entitled to appoint one or more proxy to attend and, subject to the provisions of the articles of association of the Company, vote in his stead. A proxy need not be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
2. In order to be valid, a proxy form and the power of attorney or other authority (if any) under which it is signed, or a certified copy of such power of attorney, must be deposited at the branch share registrar of the Company, Hong Kong Registrars Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, not less than 48 hours before the time fixed for holding the meeting or any adjournment thereof.
3. In relation to the proposed resolutions numbered 5 and 7 above, approval is being sought from the shareholders for the grant to the directors of a general mandate to authorise the allotment and issue of shares under the Listing Rules. The board of directors of the Company has no immediate plan to issue any new shares of the Company.
4. In relation to the proposed resolution numbered 6 above, the directors of the Company wish to state that they will exercise the powers conferred thereby to purchase shares of the Company in circumstances which they deem appropriate for the benefit of the shareholders. The board of directors of the Company may or may not repurchase any shares of the Company pursuant to the mandate to be granted under the proposed resolution numbered 6 above depending on the prevailing market conditions.
5. Delivery of an instrument appointing a proxy should not preclude a member from attending and voting in person at the above meeting or any adjournment thereof and in such event, the instrument appointing a proxy shall be deemed to be revoked.
6. In the case of joint holders of a share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto; but if more than one of such joint holders are present at the above meeting, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose, seniority shall be determined by the order in which the names stand in the register of members of the Company in respect of the joint holding.